Dr. Allen Hopper attained his PhD in medicinal chemistry from The Ohio State University in 1993 and now has more than 25 years of leadership experience in CNS drug discovery within the biotech and pharmaceutical industry. He has successfully leveraged his drug discovery expertise in leading multidisciplinary international teams from hit to lead through candidate nomination for multiple target classes of challenging CNS drug discovery programs. The drugs include preRNA splicing modulators for Huntington’s disease (Remix Therapeutics), oxysterol synthesis inhibitors (Sage Therapeutics), DHFR and CDPK-1 inhibitors for neglected parasitic infections (Vyera Pharmaceuticals), P2X7 antagonists for pain/depression and mGlu5 PAMs for cognitive deficits in schizophrenia (Lundbeck), glycine transport type 1 inhibitors for schizophrenia (Allelix Biopharmaceuticals), PDE4 inhibitors for Alzheimer’s disease and depression and PDE10 inhibitors for schizophrenia (Memory Pharmaceuticals). His work has led to the filing of 4 INDs and more than 75 published patent applications and peer-reviewed papers.